The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Summary analysis of a Phase I study with NXC-201, an academic anti-BCMA CAR-T, for R/R myeloma
In this video, Eyal Lebel, MD, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, discusses a Phase Ia/b study (NCT04720313) of NXC-201 (formerly HBI0101), an academic anti-BCMA CAR-T product, for patients with relapsed/refractory (R/R) multiple myeloma. He highlights the study’s inclusive design and high manufacturing success rate, and notes the agent’s efficacy and safety. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
